الولايات المتحدة · منصات وبيانات · TipRanks

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

نشره TipRanks · الولايات المتحدة منذ 10 س

ملخص مفصل

Luye Pharma Group ( ($HK:2186) ) has shared an update. Ruoxinlin, approved in China in November 2022 and first included in the reimbursement list in November 2024, ...

اقرأ المقال كاملًا على TipRanks سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.tipranks.com)

يستحق القراءة أيضًا

The Motley Fool

What To Expect In Markets This Week: NVDA, PANW, DIS, HD, TGT, WMT, GRRR Earnings, Kevin Warsh Speech And More

Seeking Alpha

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

ملخص مفصل

مشاركة

يستحق القراءة أيضًا

Prediction: Rigetti Computing Stock Will Be Worth This Much in 1 Year

German American Bancorp director Bawel buys $19,999 in shares

Bitcoin Faces Final Capitulation Risk: Could $40,000 Be Next?

Nvidia earnings collide with Fed’s biggest AI challenge under Warsh

What To Expect In Markets This Week: NVDA, PANW, DIS, HD, TGT, WMT, GRRR Earnings, Kevin Warsh Speech And More

Global oil market moves to surplus as Persian Gulf shipments rebound, IEA says